Amino acidic substitutions in the polymerase N-terminal region of a reassortant betanodavirus strain causing poor adaptation to temperature increase

International audienceAbstractNervous necrosis virus (NNV), Genus Betanodavirus, is the causative agent of viral encephalopathy and retinopathy (VER), a neuropathological disease that causes fish mortalities worldwide. The NNV genome is composed of two single-stranded RNA molecules, RNA1 and RNA2, encoding the RNA polymerase and the coat protein, respectively. Betanodaviruses are classified into four genotypes: red-spotted grouper nervous necrosis virus (RGNNV), striped jack nervous necrosis virus (SJNNV), barfin flounder nervous necrosis virus (BFNNV) and tiger puffer nervous necrosis virus (TPNNV). In Southern Europe the presence of RGNNV, SJNNV and their natural reassortants (in both RNA1/RNA2 forms: RGNNV/SJNNV and SJNNV/RGNNV) has been reported. Pathology caused by these genotypes is closely linked to water temperature and the RNA1 segment encoding amino acids 1–445 has been postulated to regulate viral adaptation to temperature. Reassortants isolated from sole (RGNNV/SJNNV) show 6 substitutions in this region when compared with the RGNNV genotype (positions 41, 48, 218, 223, 238 and 289). We have demonstrated that change of these positions to those present in the RGNNV genotype cause low and delayed replication in vitro when compared with that of the wild type strain at 25 and 30 °C. The experimental infections confirmed the impact of the mutations on viral replication because at 25 °C the viral load and the mortality were significantly lower in fish infected with the mutant than in those challenged with the non-mutated virus. It was not possible to challenge fish at 30 °C because of the scarce tolerance of sole to this temperature

El espacio de los editores: Nutrición Hospitalaria en 2017

Como es habitual, coincidiendo con el comienzo de un nuevo ejercicio, el Comité Editorial da cuenta del último año en Nutrición Hospitalaria (NH), de su situación general, de los cambios producidos y de los resultados obtenidos. Dos son los aspectos relevantes durante 2017, en apariencia, contrapuestos: el incremento en la visibilidad de la revista y, a la vez, la disminución en el factor de impacto Journal Citation Report (JCR)

Nervous Necrosis Virus (NNV) Booster Vaccination Increases Senegalese Sole Survival and Enhances Immunoprotection

iral encephalopathy and retinopathy (VER), caused by nervous necrosis virus (NNV), is a serious threat to Senegalese sole farming. We have previously demonstrated that immunization with an inactivated vaccine confers partial protection against the infection. However, a vaccination program must be finely adjusted to achieve the best results in terms of immune system stimulation and protection. In this study we show that a booster injection 30 days after prime vaccination increases sole survival and reduces NNV replication in brain (viral target organ). The analysis of immune-related genes expression indicated that T CD4+ lymphocytes and the proteins Mx and HERC4 may play an important role in the protection. These findings increase our understanding of sole immune response against NNV and may contribute to the development of effective protection measures.This research was funded by Ministerio de Ciencia, Innovación y Universidades (MCIUI), the Agencia Estatal de Investigación (AEI) and FEDER, grant number RTI2018-094687-B-C21. Dr. Sandra Souto was funded with a postdoctoral grant from Consellería de Cultura, Educación e Universidade, Xunta de Galicia (grant number: ED481D-2022-024). Partial funding for open access charge: Universidad de Málag

European sea bass brain DLB-1 cell line is susceptible to nodavirus: A transcriptomic study

Viral diseases are responsible for high rates of mortality and subsequent economic losses in modern aquaculture. The nervous necrosis virus (NNV) produces viral encephalopathy and retinopathy (VER), which affects the fish central nervous system. It is considered one of the most serious viral diseases in marine aquaculture, the European sea bass (Dicentrarchus labrax) being amongst the most susceptible. We have evaluated the European sea bass brain derived cell line (DLB-1) susceptibility to NNV genotypes and evaluated its transcriptomic profile. DLB-1 cells supported NNV gene transcription and replication since strains belonging to the four NNV genotypes produce cytopathic effects. Afterwards, DLB-1 cells were infected with an RGNNV strain, the one which showed the highest replication, for 12 and 72 h and an RNA-seq analysis was performed to identify potential genes involved in the host-NNV interactions. Differential expression analysis showed the up-regulation of many genes related to immunity, heat-shock proteins or apoptosis but not to proteasome or autophagy processes. These data suggest that the immune response, mainly the interferon (IFN) pathway, is not powerful enough to abrogate the infection, and cells finally suffer stress and die by apoptosis liberating infective particles. GO enrichment also revealed, for the first time, the down-regulation of terms related to brain/neuron biology indicating molecular mechanisms causing the pathogenic effect of NNV. This study opens the way to understand key elements in sea bass brain and NNV interactions.Versión del edito

Evaluación de la respuesta inmune en lenguado senegalés conferida por una vacuna inactivada frente a Betanodavirus

La necrosis nerviosa viral es una enfermedad que afecta a peces cultivados en todo el mundo. Su agente etiológico es el virus de la necrosis nerviosa, género Betanodavirus, familia Nodaviridae, que presenta un genoma compuesto por dos segmentos de RNA monocatenario. Los betanodavirus se clasifican en cuatro especies, Striped Jack-, Tiger puffer-, Redspotted grouper- y Barfin flonder nervous necrosis virus (SJNNV, TPNNV, RGNNV y BFNNV, respectivamente). En el sur de Europa se han descrito recombinantes de los segmentos genómicos de las especies SJNNV y RGNNV como agentes causantes de epizootías en lenguado senegalés y dorada. El control de esta enfermedad es de gran importancia para la acuicultura europea y la vacunación es una de las estrategias más prometedoras. Sin embargo, solo existen vacunas comercializadas contra la especie RGNNV las cuales no protegen frente a los aislados recombinantes, por lo que se ha desarrollado una vacuna inactivada utilizando el aislado recombinante SpSsIAusc160.03 que produce una moderada protección frente a la infección vírica en lenguado (Valero et al., 2021). El objetivo de este estudio es evaluar la capacidad de dicha vacuna de inducir una respuesta inmune eficaz en lenguado (Solea senegalensis). Se tomaron muestras de cerebro y riñón cefálico de lenguados vacunados y sin vacunar a 2, 3 y 7 días post-vacunación (dpv), analizándose la expresión de 106 inmunogenes mediante la plataforma OpenArray® (Gémez et al., 2020). Se detectó una respuesta inmune temprana en muestras de riñón, expresándose diferencialmente 39 y 29 genes a 2 y 3 dpv, respectivamente. Esta modulación fue significativamente menor a 7 dpv, con solo 3 genes expresados diferencialmente (DEG). En muestras de cerebro, tejido diana de la infección, se observó una menor modulación génica, detectándose expresión diferencial exclusivamente a 2 y 3 dpv (5 y 12 DEG, respectivamente). Financiación: Proyecto RTI2018-094687-B-C21/C22 del MICIU cofinanciado por FEDER.Universidad de Málaga. Campus de Excelencia Internacional Andalucía Tech

Nodavirus colonizes and replicates in the testis of gilthead seabream and European sea bass modulating its immune and reproductive functions

Viruses are threatening pathogens for fish aquaculture. Some of them are transmitted through gonad fluids or gametes as occurs with nervous necrosis virus (NNV). In order to be transmitted through the gonad, the virus should colonize and replicate inside some cell types of this tissue and avoid the subsequent immune response locally. However, whether NNV colonizes the gonad, the cell types that are infected, and how the immune response in the gonad is regulated has never been studied. We have demonstrated for the first time the presence and localization of NNV into the testis after an experimental infection in the European sea bass (Dicentrarchus labrax), and in the gilthead seabream (Sparus aurata), a very susceptible and an asymptomatic host fish species, respectively. Thus, we localized in the testis viral RNA in both species using in situ PCR and viral proteins in gilthead seabream by immunohistochemistry, suggesting that males might also transmit the virus. In addition, we were able to isolate infective particles from the testis of both species demonstrating that NNV colonizes and replicates into the testis of both species. Blood contamination of the tissues sampled was discarded by completely fish bleeding, furthermore the in situ PCR and immunocytochemistry techniques never showed staining in blood vessels or cells. Moreover, we also determined how the immune and reproductive functions are affected comparing the effects in the testis with those found in the brain, the main target tissue of the virus. Interestingly, NNV triggered the immune response in the European sea bass but not in the gilthead seabream testis. Regarding reproductive functions, NNV infection alters 17β-estradiol and 11-ketotestosterone production and the potential sensitivity of brain and testis to these hormones, whereas there is no disruption of testicular functions according to several reproductive parameters. Moreover, we have also studied the NNV infection of the testis in vitro to assess local responses. Our in vitro results show that the changes observed on the expression of immune and reproductive genes in the testis of both species are different to those observed upon in vivo infections in most of the casesMINECO and FEDER (AGL2010-20801-C02-01; AGL2010-20801-C02-02; AGL2013-43588-P); Fundación Séneca (04538/GERM/06)Versión del editor4,411

Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies

Interleukin 17 (IL-17) is a proinflammatory cytokine that has been the focus of intensive research because of its crucial role in the pathogenesis of different diseases across many medical specialties. In this context, the present review in which a panel of 13 experts in immunology, dermatology, rheumatology, neurology, hematology, infectious diseases, hepatology, cardiology, ophthalmology and oncology have been involved, puts in common the mechanisms through which IL-17 is considered a molecular target for the development of novel biological therapies in these different fields. A comprehensive review of the literature and analysis of the most outstanding evidence have provided the basis for discussing the most relevant data related to IL-17A blocking agents for the treatment of different disorders, such as psoriasis, psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, cardiovascular disorders, non alcoholic fatty liver disease, multiple sclerosis, inflammatory bowel disease, uveitis, hematological and solid cancer. Current controversies are presented giving an opening line for future research.This work was supported by Novartis Pharmaceuticals Spain

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Background Non-alcoholic steatohepatitis (NASH) is a common type of chronic liver disease that can lead to cirrhosis. Obeticholic acid, a farnesoid X receptor agonist, has been shown to improve the histological features of NASH. Here we report results from a planned interim analysis of an ongoing, phase 3 study of obeticholic acid for NASH. Methods In this multicentre, randomised, double-blind, placebo-controlled study, adult patients with definite NASH,non-alcoholic fatty liver disease (NAFLD) activity score of at least 4, and fibrosis stages F2–F3, or F1 with at least oneaccompanying comorbidity, were randomly assigned using an interactive web response system in a 1:1:1 ratio to receive oral placebo, obeticholic acid 10 mg, or obeticholic acid 25 mg daily. Patients were excluded if cirrhosis, other chronic liver disease, elevated alcohol consumption, or confounding conditions were present. The primary endpointsfor the month-18 interim analysis were fibrosis improvement (≥1 stage) with no worsening of NASH, or NASH resolution with no worsening of fibrosis, with the study considered successful if either primary endpoint was met. Primary analyses were done by intention to treat, in patients with fibrosis stage F2–F3 who received at least one dose of treatment and reached, or would have reached, the month 18 visit by the prespecified interim analysis cutoff date. The study also evaluated other histological and biochemical markers of NASH and fibrosis, and safety. This study is ongoing, and registered with ClinicalTrials.gov, NCT02548351, and EudraCT, 20150-025601-6. Findings Between Dec 9, 2015, and Oct 26, 2018, 1968 patients with stage F1–F3 fibrosis were enrolled and received at least one dose of study treatment; 931 patients with stage F2–F3 fibrosis were included in the primary analysis (311 in the placebo group, 312 in the obeticholic acid 10 mg group, and 308 in the obeticholic acid 25 mg group). The fibrosis improvement endpoint was achieved by 37 (12%) patients in the placebo group, 55 (18%) in the obeticholic acid 10 mg group (p=0·045), and 71 (23%) in the obeticholic acid 25 mg group (p=0·0002). The NASH resolution endpoint was not met (25 [8%] patients in the placebo group, 35 [11%] in the obeticholic acid 10 mg group [p=0·18], and 36 [12%] in the obeticholic acid 25 mg group [p=0·13]). In the safety population (1968 patients with fibrosis stages F1–F3), the most common adverse event was pruritus (123 [19%] in the placebo group, 183 [28%] in the obeticholic acid 10 mg group, and 336 [51%] in the obeticholic acid 25 mg group); incidence was generally mild to moderate in severity. The overall safety profile was similar to that in previous studies, and incidence of serious adverse events was similar across treatment groups (75 [11%] patients in the placebo group, 72 [11%] in the obeticholic acid 10 mg group, and 93 [14%] in the obeticholic acid 25 mg group). Interpretation Obeticholic acid 25 mg significantly improved fibrosis and key components of NASH disease activity among patients with NASH. The results from this planned interim analysis show clinically significant histological improvement that is reasonably likely to predict clinical benefit. This study is ongoing to assess clinical outcomes

El espacio de los editores: Nutrición Hospitalaria en 2017

Como es habitual, coincidiendo con el comienzo de un nuevo ejercicio, el Comité Editorial da cuenta del último año en Nutrición Hospitalaria (NH), de su situación general, de los cambios producidos y de los resultados obtenidos. Dos son los aspectos relevantes durante 2017, en apariencia, contrapuestos: el incremento en la visibilidad de la revista y, a la vez, la disminución en el factor de impacto Journal Citation Report (JCR)